Amgen Discontinues Vectibix(TM) Treatment in PACCE Trial ... - Genetic Engineering News (press release)
March 22, 2007| Amgen Discontinues Vectibix(TM) Treatment in PACCE Trial ... Genetic Engineering News (press release), NY - The PACCE trial investigated a treatment regimen that used dual biologics combined with oxaliplatin- or irinotecan-based chemotherapy. ... CORRECTING and REPLACING Amgen Discontinues Vectibix(TM) Treatment ... |
The BeSt Way to Treat Early Rheumatoid Arthritis? - Annals of Internal Medicine
March 22, 2007| The BeSt Way to Treat Early Rheumatoid Arthritis? Annals of Internal Medicine - Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med. ... |
OTN's Specialty Pharmacy, ivpcare, Selected to Dispense Newly ... - SYS-CON Media
March 22, 2007| OTN's Specialty Pharmacy, ivpcare, Selected to Dispense Newly ... SYS-CON Media, NJ - The US Food and Drug Administration approved Tykerb on March 13, 2007, for the treatment of advanced or metastatic breast cancer in combination with ... |
Eisai to Acquire Morphotek - campus med
March 22, 2007| Eisai to Acquire Morphotek campus med, Germany - ... to enrich its pipeline that already includes therapeutic antibody leads for the treatment of cancer, rheumatoid arthritis, and infectious disease. ... |
OTN's Specialty Pharmacy, ivpcare, Selected to Dispense Newly ... - PR Newswire (press release)
March 22, 2007| OTN's Specialty Pharmacy, ivpcare, Selected to Dispense Newly ... PR Newswire (press release), NY - The US Food and Drug Administration approved Tykerb on March 13, 2007, for the treatment of advanced or metastatic breast cancer in combination with ... |